ClinicalTrials.gg
Active, not recruitingNCT06565065Updated Aug 19, 2026

ImmunoBoost: The Lymphatic Osteopathic Manipulative Treatment Protocol Study

An interventional study of Osteopathic Manipulative Treatment (OMT) and Sham Light Touch in Healthy, sponsored by Western University of Health Sciences. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Western University of Health Sciences · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to determine whether osteopathic manipulative treatment (OMT) enhances immune system readiness in healthy adults compared to exercise or sham light treatment. Specifically, the goal of this study is to assess circulating immune cells and signaling molecules in the blood in response to these various treatments.

It aims to compare: Complete Blood Counts (CBC) and blood immune signaling molecule levels in healthy adults in response to OMT, sham light touch, and exercise, with measurements taken at multiple time points.

Researchers will compare immune blood cells and signaling molecules in response to OMT versus sham light touch and exercise within the same group of healthy adults measured at three time points for each of the three total visits.

Participants will do a 15-minute OMT session, a 15-minute light sham session, or a 15-minute exercise session at each of their three separate visits (they will do one of each over the course of their 3 appointments in random order). They will have three blood draws taken at each of those three visits. They will also fill out a Global Physical Activity Questionnaire (GPAQ) survey to assess their level of physical activity throughout the study.

Read the detailed description

This clinical trial is a follow-up on a recent trial demonstrating an enhanced immune response in participants who received lymphatic osteopathic manipulative treatment (OMT) with each of their COVID-19 mRNA vaccinations. Similar immune enhancement was observed in a pilot study with OMT in conjunction with the Hepatitis B vaccine. Additionally, animal studies have shown that lymphatic pump OMT can cause transient increases in the movement of lymphatic fluid, immune cells, and signaling molecules throughout the body and bloodstream. These findings were further supported by in vitro studies on fibroblasts, where OMT led to significant increases in circulating cytokines. There are studies that suggest that combining physical exercise with vaccination can also improve immune responses. To parse out these effects observed in OMT and exercise studies and provide the mechanisms underlying the observed immune enhancements, this clinical trial will be conducted.

This study is designed as a crossover, self-controlled, comparative effectiveness randomized clinical trial. A total of 30 healthy individuals who meet all inclusion/exclusion criteria will be recruited. Participants will then fill out a health questionnaire during the screening process to confirm their eligibility.

Each participant will be randomly assigned to one of three intervention sequences to maintain blinding and control for order and sequencing effects. The intervention sequences are as follows:

  • Order 1: Day 0: OMT, Week 3: Sham, Week 6: Exercise
  • Order 2: Day 0: Sham, Week 3: OMT, Week 6: Exercise
  • Order 3: Day 0: Exercise, Week 3: OMT, Week 6: Sham

There will be a 3-week washout period between each intervention. Participants will complete the Global Physical Activity Questionnaire (GPAQ) survey to identify their current level of exercise at each visit. They will also be monitored for any adverse effects following each intervention.

All treatment protocols will be done for a 12-minute timeframe per session. Participants will have three blood draws at each visit: at baseline, five minutes after intervention, and four hours after intervention. The primary outcome measures will include cytokine levels and circulating leukocyte levels, which will be compared across the different intervention sequences.

This study aims to provide a deeper understanding of the mechanism by which lymphatic OMT alters the immune system. It will also compare these effects to the mechanisms of exercise.

02

Conditions studied

  • Healthy

Keywords

  • Osteopathic Manipulative Treatment
  • Lymphatic Pump Treatment
  • Immune System
  • OMT
  • Complete Blood Count
  • Cytokines
03

In context

Lead sponsor

Western University of Health Sciences is the lead sponsor of 22 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals must be 18 years or older.
  • Individuals must provide .
  • Individuals must be healthy with a under 30, with no primary or secondary immune deficiency or disease/must not be .
  • Individuals must not be using or recently have used any immune-altering medications such as , cyclosporin, tacrolimus, and pimecrolimus
  • Individuals must not have had lymphatic OMT or other physical manipulation such as acupuncture, physical therapy, chiropractic, or massage therapy in the previous four weeks before study enrollment.
  • Individuals must have the ability to receive OMT with lymphatic techniques.
  • Individuals must be able to tolerate 12 minutes of moderate physical activity.
  • Individuals must not be pregnant or breastfeeding.
  • Individuals must not have had a splenectomy or other spleen or oncologic surgery within the past 6 months.
  • Individuals must be infection-free for the past 6 weeks before starting the study and have not received any immunizations within the past 6 weeks.
  • Individuals must be willing to avoid strenuous activity at least 24 hours before each visit.
  • Individuals must be willing to abstain from moderate to intense activity in the 4 hours between their 2nd blood draw and their final blood draw at each of their three visits.

Exclusion criteria

Exclusion Criteria:

  • Individuals are younger than 18 years of age.
  • Individuals who do not provide .
  • Individuals with a over 30, or with primary or secondary immune deficiency or disease or is .
  • Individuals using or recently have used any immune-altering medications such as , cyclosporin, tacrolimus, and pimecrolimus
  • Individuals who have had lymphatic OMT or other physical manipulation such as acupuncture, physical therapy, chiropractic, or massage therapy in the previous four weeks before study enrollment.
  • Individuals who don't have the ability to receive OMT with lymphatic techniques.
  • Individuals who cannot tolerate 12 minutes of moderate physical activity.
  • Individuals who are pregnant or breastfeeding.
  • Individuals who have had a splenectomy or other spleen or oncologic surgery within the past 6 months.
  • Individuals who have had an infection in the 6 weeks before starting the study and or have received any immunizations within the past 6 weeks.
  • Individuals not willing to avoid strenuous activity at least 24 hours before each visit.
  • Individuals not willing to abstain from moderate to intense activity in the 4 hours between their 2nd blood draw and their final blood draw at each of their three visits.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Order 1 - Day 0: OMT, Week 3: Sham, Week 6: Exercise

    Osteopathic Manipulative Treatment (OMT) followed by a 3-week washout period and then: Sham protocol followed by a 3-week washout period and then: Exercise protocol.

    Procedure: Osteopathic Manipulative Treatment (OMT) · Other: Sham Light Touch · Other: Exercise Protocol

  • Experimental
    Order 2 - Day 0: Sham, Week 3: OMT, Week 6: Exercise

    Sham protocol followed by a 3-week washout period and then: Osteopathic Manipulative Treatment (OMT) followed by a 3-week washout period and then: Exercise protocol.

    Procedure: Osteopathic Manipulative Treatment (OMT) · Other: Sham Light Touch · Other: Exercise Protocol

  • Experimental
    Order 3 - Day 0: Exercise, Week 3: OMT, Week 6: Sham

    Exercise protocol followed by a 3-week washout period and then: Osteopathic Manipulative Treatment (OMT) followed by a 3-week washout period and then: Sham protocol.

    Procedure: Osteopathic Manipulative Treatment (OMT) · Other: Sham Light Touch · Other: Exercise Protocol

Interventions

  • ProcedureOsteopathic Manipulative Treatment (OMT)

    A full standardized lymphatic protocol will be performed, including thoracic inlet left and right, thoracoabdominal release, pelvic diaphragm release, pedal pump, splenic pump, and abdominal lymphatic pump. This treatment will be done by systematically working down and back up. The protocol will last a total of 12 minutes for each participant

  • OtherSham Light Touch

    A full standardized 12-minute session in which treaters will mimic various osteopathic manipulative techniques at specific anatomical locations without applying pressure or manipulation.

  • OtherExercise Protocol

    A full standardized moderate-intensity physical activity as defined by the Centers for Disease Control (CDC). Target heart rate for moderate-intensity exercise should be between 64 and 76% of maximum heart rate. To estimate age-related heart rate, subjects' age will be subtracted from 220. Then, that number will be multiplied by 75%, which will be standardized across all subjects in the study. Heart rate will be monitored with the use of an attached pulse-ox monitor. Treadmill speed will be adjusted accordingly so that each subject maintains a heart rate of 75% of their maximum heart rate. A brisk walk will be done on a flat treadmill and no incline will be utilized. Subjects will be allowed a minute of warm-up to get to the appropriate pace/target heart rate.

06

What researchers measure

Primary outcomes

  1. Complete Blood Count (CBC) with differential

    CBC with differential will be evaluated to identify the number of circulating plasma leukocytes for each intervention for each of the three interventions at three time points for each visit/intervention. This test will help us identify levels of erythrocytes, platelets, and leukocytes, including neutrophils, lymphocytes, monocytes, eosinophils, and basophils. This will be compared across time points for OMT, sham treatment, and exercise.

    Time frame: Baseline to 5 minutes post-intervention to 4 hours post-intervention.

Secondary outcomes

  1. Pro-Inflammatory cytokine profiling

    V-Plex Human Proinflammatory Panel I (4-Plex) will be used to identify cytokine profiles, including including IL-6 (Interleukin-6), IL-1β (Interleukin-1 beta), INF-γ (Interferon-gamma), and TNF-α (Tumor Necrosis Factor-alpha). This will be evaluated for each of the three interventions at three time points for each visit/intervention. This will be compared across time points for OMT, sham treatment, and exercise.

    Time frame: Baseline to 5 minutes post-intervention to 4 hours post-intervention.

  2. Evaluation of safety based on reported adverse events

    Documentation of any adverse events to OMT, sham treatment, or exercise protocol.

    Time frame: Through study completion, an average of 6 weeks.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06565065
Lead sponsor
Western University of Health Sciences
Collaborators
American Osteopathic Foundation
Responsible party
Brian Loveless (Chief Medical Officer, WesternU Health/ Professor or OMM/MMM WesternU COMP, Western University of Health Sciences) — Principal investigator
First posted
Aug 21, 2024
Start date
Jul 14, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Aug 19, 2026

Study contacts

Brian Loveless, DO
principal investigator · Professor of NMM/OMM and Chief Medical Officer of WesternU Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion